Tamoxifen 20mg/tab 50 Tabletten by Nassa Labs

Usage

1. Step 1 — Calculate your clearance window: identify the longest-acting compound from your cycle and determine its expected plasma clearance timeline based on ester half-life (short ester: ~3–4 days; enanthate/cypionate: 14–21 days; undecanoate/decanoate: up to 28 days).
2. Step 2 — Schedule a blood panel: at the anticipated clearance date, draw serum total testosterone and LH to confirm androgen levels have fallen sufficiently before starting Tamoxifen Citrate.
3. Step 3 — Confirm your start date: use the blood values (total testosterone below ~300 ng/dL, LH below 1.0 mIU/mL) as objective confirmation — not subjective symptoms — before opening your first blister.
4. Step 4 — Begin induction dosing: take two 20 mg tablets (40 mg total) daily with water at the same time each day during weeks one and two; the 20 mg denomination eliminates any need for tablet splitting at this phase.
5. Step 5 — Transition to maintenance: at week three, reduce to one 20 mg tablet daily and repeat a blood panel mid-protocol to verify LH and FSH are trending upward as expected.
6. Step 6 — Complete the protocol and exit: do not stop Tamoxifen Citrate abruptly mid-trend; complete the planned phase duration, draw a final blood panel to confirm testosterone recovery, and discontinue once values are within the normal reference range.

Warnings

Frequently asked questions

How many days after my last injection should I wait before starting Tamoxifen Citrate 20mg?

The wait period depends entirely on the ester attached to the compound you used. Short esters (propionate, acetate) clear within three to four days; standard long esters (enanthate, cypionate) require 14–21 days; ultra-long esters such as undecanoate or decanoate may demand up to four weeks. Starting Tamoxifen Citrate before this window closes means introducing a SERM while suppressive androgens remain active, which blunts the recovery signal.

What blood test results tell me it is safe to begin PCT with Tamoxifen Citrate?

Serum total testosterone falling below approximately 300 ng/dL combined with LH reading below 1.0 mIU/mL indicates that exogenous androgen has cleared sufficiently to allow SERM-driven stimulation to take effect. Without these objective markers, relying on how you feel alone risks starting too early or too late. A blood panel drawn at the expected clearance date provides the most reliable green light for initiating Tamoxifen Citrate therapy.

What are the consequences of starting PCT too early before androgens have fully cleared?

Starting Tamoxifen Citrate while residual exogenous androgens are still biologically active produces no net recovery benefit — the pituitary continues to register suppressive androgen signalling and does not meaningfully upregulate LH and FSH in response to the SERM. This effectively delays genuine recovery by the number of days the SERM was used prematurely. The 50-tablet count in this pack absorbs the induction phase correctly once the start point is properly timed.

Does the 20mg per tablet strength of Nassa Labs Tamoxifen Citrate make front-loading easier compared to lower-dose tablets?

Yes. At 20 mg per tablet — the highest unit dose in the Tamoxifen Citrate tablet format — a two-tablet daily induction delivers exactly 40 mg without splitting or combining different-strength tablets. Lower-denomination tablets (5 mg or 10 mg) require four to eight units per day to reach equivalent induction doses, increasing the risk of dosing inconsistency. The 20 mg denomination simplifies the arithmetic of the critical opening phase of PCT.

Can I split a Nassa Labs Tamoxifen Citrate 20mg tablet to achieve a 10mg maintenance dose?

Tablet splitting is possible but introduces minor content variability at the split face. The preferred approach is to use the full 20 mg tablet once daily during the maintenance phase if the protocol design permits, or to taper frequency rather than tablet size. Because HPLC verification confirms the declared 20 mg content in every Nassa Labs batch, the starting content per tablet is analytically established — any variance introduced by splitting is mechanical, not formulation-related. (2) angle_used

Manufacturer

The API sourcing framework underlying Nassa Labs Tamoxifen Citrate 20mg/tab is the dimension the company has chosen to anchor transparency for this product — specifically, the traceability of the Tamoxifen Citrate active pharmaceutical ingredient from certified synthesis source through to the finished tablet. Nassa Labs sources Tamoxifen Citrate API exclusively from suppliers who provide a full certificate of analysis referencing synthesis route, purity grade, and residual solvent profile under ICH Q3C guidelines; those supplier documents are retained as part of the lot record and are available for distributor review alongside the finished-product HPLC content certificate. The finished tablet undergoes content quantification against a certified Tamoxifen Citrate reference standard as a separate, post-tableting release gate — confirming that the API's declared purity at the input stage is preserved through the granulation and compression process. LAL endotoxin screening completes the dual-gate release sequence before any batch is cleared for outbound distribution.